Tiger Brokers

Telix Pharmaceuticals Q1 Revenue Rises 24%; Shares Gain 6%

MT Newswires Live
Apr 07

Telix Pharmaceuticals (ASX:TLX) reported first-quarter revenue of $230 million, up 24% from a year earlier, according to a Tuesday filing with the Australian bourse.

First-quarter revenue for the company's Precision Medicine segment increased 23% year over year to $186 million, per the filing.

Telix reaffirmed its full-year revenue guidance of $950 million to $970 million, and its research and development expenditure outlook of $200 million to $240 million.

Additionally, the company said part 1 of the global phase 3 study of its TLX591-Tx prostate cancer therapy candidate met safety and other objectives, with no new safety signals observed.

Telix shares gained 6% in recent Australian trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10